Human Genetics

, Volume 118, Issue 3–4, pp 393–403 | Cite as

Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks

  • Xuelian He
  • Yongjian Lu
  • Nilmani Saha
  • Hongyuan Yang
  • Chew-Kiat HengEmail author
Original Investigation


Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice. To explore the possible impact of ACAT2 gene variants on CAD susceptibility and plasma lipid levels, three polymorphisms, 41A>G (Glu>Gly), 734C>T (Thr>Ile), and IVS4-57_58 ins48 bp (D/I), were genotyped in 809 CAD patients (CAD+) and 1,304 controls (CAD−) from three distinct Singaporean ethnic groups (1,228 Chinese, 367 Malays and 518 Indians). The 734T allele frequency was significantly lower in CAD+ (0.20) than CAD− (0.26) in Chinese (P=0.003) and I allele of D/I was significantly higher in CAD+ (0.17) than CAD− (0.10) in Indians (P=0.011). The 41G allele was significantly more frequent among normolipidemic (0.19) than dyslipidemic (0.13) individuals in Chinese (P=0.008). In normolipidemic females, 734C>T was associated with apoA1, apoB and lipoprotein (a) in Indians, and with apoA1 in Malays, whereas 41A>G is associated with total cholesterol in Indians. The 734C>T polymorphism was in almost complete linkage disequilibrium (LD) with the IVS4-57_58 ins48 bp and in very strong LD with 41A>G in all the three ethnic groups. In the normolipidemic females, the AG/CT had much higher apoB than AA/CC in Indians. We found that the three ACAT2 polymorphisms studied are associated with CAD risk and plasma lipid levels but their effects are not consistent across genders and ethnic groups.


ACAT2 Coronary artery disease Polymorphisms Plasma lipids Haplotypes Linkage disequilibrium 



This study was supported by grant NMRC/0408/2000 from the Singapore National Medical Research Council. Excellent technical assistance rendered by Ms. Karen Lee is also gratefully acknowledged.


  1. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio S, Farese RV Jr (2000) Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest 105(6):711–719PubMedCrossRefGoogle Scholar
  2. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Sheness GS, Rudel LL (1998) Identification of a form of acyl-CoA: cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem 273:26747–26754PubMedCrossRefGoogle Scholar
  3. Bocan TM, Krause BR, Rosebury WS, Muller SB, Lu X, Dagle C, Major T, Lathia C, Lee H (2000) The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 20:70–79PubMedGoogle Scholar
  4. Borradaile NM, de Dreu LE, Barrett PH, Huff MW (2002) Inhibition of hepatocyte ApoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res 43:725–734CrossRefGoogle Scholar
  5. Buhman KK, Accad M, Novak S, Choi RS, Wong JS, Hamilton RL, Turley S, Farese RV Jr (2000) Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med 6:1341–1347PubMedCrossRefGoogle Scholar
  6. Burnett JR, Wilcox LJ, Huff MW (1999) Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Clin Chim Acta 286:231–242PubMedCrossRefGoogle Scholar
  7. Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW (1999) Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 40:1317–1327PubMedGoogle Scholar
  8. Carr TP, Hamilton RL Jr, Rudel (1995) ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res 36:25–36PubMedGoogle Scholar
  9. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, Welch CB, Lusis AJ, Spencer TA, Krause BR, Erickson SK, Farese RV Jr (1998) ACAT-2, a second mammalian acyl-CoA: cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem 273:26755–26764PubMedCrossRefGoogle Scholar
  10. Chang CC, Huh HY, Cadigan KM, Chang TY (1993) Molecular cloning and functional expression of human acyl-coenzyme A: cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem 268:20747–20755PubMedGoogle Scholar
  11. Chang CC, Sakashita N, Ornvold K, Lee O, Chang ET, Dong R, Lin S, Lee CY, Strom SC, Kashyap R, Fung JJ, Farese RV Jr, Patoiseau JF, Delhon A, Chang TY (2000) Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem 275:28083–28092PubMedGoogle Scholar
  12. Erickson SK, Shrewsbury MA, Brooks C, Meyer DJ (1980) Rat liver acyl-coenzyme A: cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J Lipid Res 21:930–941PubMedGoogle Scholar
  13. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrification. Clin Chem 18:499–502PubMedGoogle Scholar
  14. Heng CK, N. Saha, J Tay (1995) Lack of association of apolipoprotein E polymorphism with plasma Lp(a) levels in the Chinese. Clin Genet 48:113–119PubMedCrossRefGoogle Scholar
  15. Hill WG, Robertson A (1968) Linkage disequilibrium in finite populations. Theor Appl Genet 38:226–231CrossRefGoogle Scholar
  16. Hughes K, Lun KC, Yeo PP (1990a) Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. I. Differences in mortality. J Epidemiol Community Health 44:24–28PubMedCrossRefGoogle Scholar
  17. Hughes K, Yeo PP, Lun KC, Thai AC, Sothy SP, Wang KW, Cheah JS, Phoon WO, Lim P (1990b) Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Community Health 44:29–35PubMedGoogle Scholar
  18. Katsuren K, Tamura T, Arashiro R, Takata K, Matsuura T, Niikawa N, Ohta T (2001) Structure of the human acyl-CoA:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia. Biochim Biophys Acta 1531:230–240PubMedGoogle Scholar
  19. Kellner-Weibel G, Jerome WG, Small DM, Warner GJ, Stoltenborg JK, Kearney MA, Corjay MH, Phillips MC, Rothblat GH (1998) Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol 18:423–431PubMedGoogle Scholar
  20. Lee O, Chang CC, Lee W, Chang TY (1998) Immunodepletion experiments suggest that acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J Lipid Res 39:1722–1727PubMedGoogle Scholar
  21. Lee RG, Kelley KL, Sawyer JK, Farese RV Jr, Parks JS, Rudel LL (2004) Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95(10):998–1004PubMedCrossRefGoogle Scholar
  22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421Google Scholar
  23. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL (1998) Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J Biol Chem 273:26765–26771PubMedCrossRefGoogle Scholar
  24. Parzer S, Mannhalter C (1991) A rapid method for the isolation of genomic DNA from citrated whole blood. Biochem J 273:229–231PubMedGoogle Scholar
  25. Rudel LL, Lee RG, Parini P (2005) ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25(6):1112–1118PubMedCrossRefGoogle Scholar
  26. Song BL, Qi W, Yang XY, Chang CC, Zhu JQ, Chang TY, Li BL (2001) Organization of human ACAT-2 gene and its cell-type-specific promoter activity. Biochem Biophys Res Commun 282:580–588PubMedCrossRefGoogle Scholar
  27. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) (1993), JAMA 269(23):3015–3023Google Scholar
  28. Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, Rudel LL, Farese RV Jr (2003) Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 100:1262–1267PubMedCrossRefGoogle Scholar
  29. Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y, Oka T, Perrey S, Tamura Y, Ohashi K, Okazaki H, Yahagi N, Shionoiri F, Iizuka Y, Harada K, Shimano H, Yamashita H, Gotoda T, Yamada N, Ishibashi S (2000) Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem 275(28):21324–21330PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Xuelian He
    • 1
  • Yongjian Lu
    • 2
  • Nilmani Saha
    • 1
  • Hongyuan Yang
    • 2
  • Chew-Kiat Heng
    • 1
    Email author
  1. 1.Department of PaediatricsNational University of SingaporeSingaporeSingapore
  2. 2.Department of BiochemistryNational University of SingaporeSingaporeSingapore

Personalised recommendations